Supplementary Fig. S1 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma

Sato, Shinya; Nakagawa, Masatoshi; Terashima, Takeshi; Morinaga, Soichiro; Miyagi, Yohei; Yoshida, Eisaku; Yoshimura, Toru; Seiki, Motoharu; Kaneko, Shuichi; Ueno, Makoto; Yamashita, Taro; Koshikawa, Naohiko

doi:10.1158/2767-9764.24147643.v1

crc-23-0087-s01.pdf (1.58 MB)

Supplementary Fig. S1 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma

journal contribution

posted on 2023-09-15, 14:20 authored by Shinya Sato, Masatoshi Nakagawa, Takeshi Terashima, Soichiro Morinaga, Yohei Miyagi, Eisaku Yoshida, Toru Yoshimura, Motoharu Seiki, Shuichi Kaneko, Makoto Ueno, Taro Yamashita, Naohiko Koshikawa

(A) Schematic of recombinant EphA2-FL, EphA2-NF and stem portion. FLAG-tag was added at C-terminus. (B) These recombinant proteins were detected by anti-FLAG mAb and anti-EphA2-N-termius pAb.

Funding

Abbott Laboratories (Abbott)

Japan Agency for Medical Research and Development (AMED)

MEXT | Japan Society for the Promotion of Science (JSPS)

Princess Takamatsu Cancer Research Fund

History

ARTICLE ABSTRACT

EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.